Summary Tonix Pharmaceuticals Holding Corp (Tonix), formerly Tamandare Explorations Inc, is a provider of pharmaceutical products to address public health challenges. The company develops pharmaceutical products and treatments for disorders of the central nervous system which include fibromyalgia, post traumatic stress disorder and episodic tension-type headache. Its products comprise oral formulation, smallpox vaccine, disintegrating sublingual tablets and tonmya. It offers TNX-801, a virus vaccine, which is used to prevent smallpox. Tonix’s disintegrating sublingual tablets product is a dose and formulation of cyclobenzaprine and is used for the treatment of fibromyalgia and post-traumatic stress disorder. It sells its products through a network of distributors across the US. Tonix is headquartered in New York, the US. Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.... Research Beam Model: Research Beam Product ID: 1995418 250 USD New
Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 74
  • Publisher : GlobalData
 
 
 
Summary

Tonix Pharmaceuticals Holding Corp (Tonix), formerly Tamandare Explorations Inc, is a provider of pharmaceutical products to address public health challenges. The company develops pharmaceutical products and treatments for disorders of the central nervous system which include fibromyalgia, post traumatic stress disorder and episodic tension-type headache. Its products comprise oral formulation, smallpox vaccine, disintegrating sublingual tablets and tonmya. It offers TNX-801, a virus vaccine, which is used to prevent smallpox. Tonix’s disintegrating sublingual tablets product is a dose and formulation of cyclobenzaprine and is used for the treatment of fibromyalgia and post-traumatic stress disorder. It sells its products through a network of distributors across the US. Tonix is headquartered in New York, the US.

Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 11
Equity Offering 12
Tonix Pharma Plans to Raise up to USD9 Million in Public Offering of Shares 12
Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 13
Tonix Pharma Raises USD5.2 Million in Public Offering of Units 15
Tonix Pharma Raises Funds in Private Placement of Shares 17
Tonix Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 18
Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 20
Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 22
Tonix Pharma to Raise USD8 Million in Private Placement of Shares 24
Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 26
Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 28
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 30
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 32
Debt Offering 33
Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 33
Acquisition 34
Tamandare Explorations Acquires TONIX Pharma 34
Tonix Pharmaceuticals Holding Corp - Key Competitors 35
Tonix Pharmaceuticals Holding Corp - Key Employees 36
Tonix Pharmaceuticals Holding Corp - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 14, 2017: Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update 38
Apr 17, 2017: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update 40
Nov 10, 2016: Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results 42
Aug 08, 2016: Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update 43
May 09, 2016: Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update 45
Mar 04, 2016: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update 47
Corporate Communications 49
Feb 25, 2016: Tonix Pharmaceuticals Appoints Chief Financial Officer 49
Jan 08, 2016: Tonix Pharmaceuticals Announces Management Change 50
Product News 51
11/02/2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference 51
08/15/2016: Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Re 52
06/03/2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention 53
01/10/2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference 54
Product Approvals 55
Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA 55
Clinical Trials 56
Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder 56
Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) 57
Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD 58
Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting 59
Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress 60
Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016 61
Sep 06, 2016: Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update 62
Aug 29, 2016: Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder 63
Jul 26, 2016: Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia 65
Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia 66
May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting 67
May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting 69
May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) 70
May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia 72
Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tonix Pharmaceuticals Holding Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 11
Tonix Pharma Plans to Raise up to USD9 Million in Public Offering of Shares 12
Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 13
Tonix Pharma Raises USD5.2 Million in Public Offering of Units 15
Tonix Pharma Raises Funds in Private Placement of Shares 17
Tonix Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 18
Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 20
Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 22
Tonix Pharma to Raise USD8 Million in Private Placement of Shares 24
Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 26
Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 28
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 30
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 32
Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 33
Tamandare Explorations Acquires TONIX Pharma 34
Tonix Pharmaceuticals Holding Corp, Key Competitors 35
Tonix Pharmaceuticals Holding Corp, Key Employees 36
Tonix Pharmaceuticals Holding Corp, Other Locations 37
Tonix Pharmaceuticals Holding Corp, Subsidiaries 37
List of Figures
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter